[go: up one dir, main page]

PE20091727A1 - Agentes terapeuticos antivirales - Google Patents

Agentes terapeuticos antivirales

Info

Publication number
PE20091727A1
PE20091727A1 PE2009000334A PE2009000334A PE20091727A1 PE 20091727 A1 PE20091727 A1 PE 20091727A1 PE 2009000334 A PE2009000334 A PE 2009000334A PE 2009000334 A PE2009000334 A PE 2009000334A PE 20091727 A1 PE20091727 A1 PE 20091727A1
Authority
PE
Peru
Prior art keywords
oxo
alkyl
therapeutic agents
treatment
antiviral therapeutic
Prior art date
Application number
PE2009000334A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Pooran Chand
Pravin L Kotian
Minwan Wu
V Satish Kumar
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PE20091727A1 publication Critical patent/PE20091727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00—Road transport of goods or passengers
    • Y02T10/10—Internal combustion engine [ICE] based vehicles
    • Y02T10/30—Use of alternative fuels, e.g. biofuels

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE B ES UN ANILLO CARBOCICLICO O HETEROCICLICO DE 5, 6, 7 U 8 ELEMENTOS QUE COMPRENDE UNO O MAS ENLACES DOBLES Y QUE ESTA OPCIONALMENTE SUSTITUIDO CON OXO, Br, CN, ENTRE OTROS; R1 ES H, F, NraRb, ENTRE OTROS; Ra Y Rb SON H, ALQUILO C1-C6, ALQUINILO C2-C10, ENTRE OTROS; R2 ES UN GRUPO NUCLEOSIDO DE AZUCAR TAL COMO RIBOSA, ARABINOSA, 2,3-DESOXIRIBOSA, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (88e), (93f), ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE POLIMERASAS VIRALES DEL ADN Y EL ARN Y SON UTILES PARA EL TRAMIENTO DE INFECCIONES VIRALES TALES COMO HCV, HIV Y HBV, O PARA EL TRATAMIENTO DEL CANCER
PE2009000334A 2008-03-05 2009-03-05 Agentes terapeuticos antivirales PE20091727A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3405308P 2008-03-05 2008-03-05
US7937008P 2008-07-09 2008-07-09

Publications (1)

Publication Number Publication Date
PE20091727A1 true PE20091727A1 (es) 2009-12-04

Family

ID=41054287

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000334A PE20091727A1 (es) 2008-03-05 2009-03-05 Agentes terapeuticos antivirales

Country Status (16)

Country Link
US (2) US7994139B2 (es)
EP (1) EP2265275A2 (es)
JP (1) JP2011525171A (es)
KR (1) KR20100137494A (es)
CN (1) CN102834513A (es)
AR (1) AR071745A1 (es)
AU (1) AU2009221770A1 (es)
BR (1) BRPI0910388A2 (es)
CA (1) CA2717173A1 (es)
EA (1) EA201070988A1 (es)
IL (1) IL207826A0 (es)
MX (1) MX2010009646A (es)
NZ (1) NZ588179A (es)
PE (1) PE20091727A1 (es)
TW (1) TW200942243A (es)
WO (1) WO2009111653A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390188T3 (es) * 2007-01-12 2012-11-07 Biocryst Pharmaceuticals, Inc. Análogos de nucleósidos antivirales
DK2155758T3 (da) * 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
US20090247750A1 (en) * 2008-03-28 2009-10-01 Biocryst Pharmaceuticals, Inc. Process for preparing nucleoside analogs
AP3237A (en) 2008-04-23 2015-04-30 Gilead Sciences Inc 1'-Substituted carba-nucleoside analogs for antiviral treatment
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
HRP20130862T1 (hr) 2009-09-21 2013-10-25 Gilead Sciences, Inc. Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SI2595980T1 (sl) 2010-07-22 2014-11-28 Gilead Sciences, Inc. Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij
JP5902698B2 (ja) 2010-10-15 2016-04-13 バイオクライスト ファーマシューティカルズ， インコーポレイテッド ポリメラーゼの阻害のための方法および組成物
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
US8906929B2 (en) * 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9540393B2 (en) * 2013-03-14 2017-01-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN104946646B (zh) * 2014-03-25 2020-03-31 中国医学科学院基础医学研究所 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
LT3785717T (lt) 2015-09-16 2022-04-11 Gilead Sciences, Inc. Coronaviridae infekcijų gydymo būdai
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
TWI767903B (zh) 2016-03-06 2022-06-21 美商百歐克斯製藥公司 用於治療茲卡病毒感染之方法及組合物
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
HRP20250266T1 (hr) 2017-02-01 2025-04-25 Atea Pharmaceuticals, Inc. Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734B1 (en) 2017-07-11 2024-11-13 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
CA3171648A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
DK4204421T3 (da) 2020-08-27 2024-05-27 Gilead Sciences Inc Forbindelser og fremgangsmåder til behandling af virale infektioner
CN117120444A (zh) 2021-04-16 2023-11-24 吉利德科学公司 使用酰胺制备卡巴核苷的方法
EP4355319A4 (en) 2021-06-17 2025-01-22 ATEA Pharmaceuticals, Inc. BENEFICIAL ANTI-HCV COMBINATION THERAPY
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
TWI867455B (zh) 2022-03-02 2024-12-21 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144373B1 (en) 1999-01-13 2005-10-19 Genentech, Inc. Serine protease inhibitors
JP2002279640A (ja) 2001-03-21 2002-09-27 Ricoh Co Ltd ウォブル検出回路とその装置
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
RU2006109491A (ru) 2003-08-27 2006-08-10 Байота, Инк. (Au) Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN101166750A (zh) 2004-10-29 2008-04-23 拜奥克里斯特制药公司 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
EA200701850A1 (ru) 2005-02-28 2008-02-28 Дженелабс Текнолоджис, Инк. Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
ES2390188T3 (es) 2007-01-12 2012-11-07 Biocryst Pharmaceuticals, Inc. Análogos de nucleósidos antivirales
DK2155758T3 (da) 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer

Also Published As

Publication number Publication date
CA2717173A1 (en) 2009-09-11
WO2009111653A3 (en) 2011-09-22
EA201070988A1 (ru) 2011-12-30
MX2010009646A (es) 2010-09-28
US7994139B2 (en) 2011-08-09
JP2011525171A (ja) 2011-09-15
BRPI0910388A2 (pt) 2019-06-11
US20090227524A1 (en) 2009-09-10
EP2265275A2 (en) 2010-12-29
US20120142617A1 (en) 2012-06-07
KR20100137494A (ko) 2010-12-30
CN102834513A (zh) 2012-12-19
TW200942243A (en) 2009-10-16
AR071745A1 (es) 2010-07-14
WO2009111653A2 (en) 2009-09-11
AU2009221770A1 (en) 2009-09-11
IL207826A0 (en) 2010-12-30
NZ588179A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
PE20091727A1 (es) Agentes terapeuticos antivirales
UY31476A1 (es) Nucleosidos 2' , 4' -sustituidos como agentes antivirales
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
PE20191552A1 (es) Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerizacion de fijacion a nucleotidos p3 (nlrp3)
JP2018088924A5 (es)
PE20120257A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
GT200500221A (es) Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.
PE20151318A1 (es) Analogos de 2'-cloro nucleosido para infeccion por vhc
MX2020013384A (es) Compuestos de comarina sustituidos con amina exocíclica y sus usos como etiquetas fluorescentes.
CL2013003053A1 (es) Compuesto que comprende un oligonucleotido modificado que consiste en de 10 a 30 nucleósidos unidos y definidos por un grupo de secuencias específicas; composicion que comprende dicho compuesto; uso para tratar enfermedades relacionadas con el virus de la hepatitis b (vhb).
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
PE20160658A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
PE20050462A1 (es) COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5)
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA
CL2017001769A1 (es) Compuestos derivados de nucleosidos, nucleotidos y análogos de los mismos; composición farmacéutica que los comprende; útiles en el tratamiento de la hepatitis c (divisional de la solicitud 1699-2015).
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
PE20091458A1 (es) Compuestos heterociclicos antiviricos
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
MX2020001158A (es) Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.
CO6382185A2 (es) Compuestos nucleosidos antivirales
EA201592075A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
AR089650A1 (es) Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
CO6321235A2 (es) Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral
MD4403B1 (ro) Compuşi antivirali în bază de dihidroxiizocromen-naftoimidazoli condensaţi

Legal Events

Date Code Title Description
FC Refusal